These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 20190739)

  • 21. Inhibition of Rho kinases enhances the degradation of mutant huntingtin.
    Bauer PO; Wong HK; Oyama F; Goswami A; Okuno M; Kino Y; Miyazaki H; Nukina N
    J Biol Chem; 2009 May; 284(19):13153-64. PubMed ID: 19278999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interaction with polyglutamine-expanded huntingtin alters cellular distribution and RNA processing of huntingtin yeast two-hybrid protein A (HYPA).
    Jiang YJ; Che MX; Yuan JQ; Xie YY; Yan XZ; Hu HY
    J Biol Chem; 2011 Jul; 286(28):25236-45. PubMed ID: 21566141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model.
    Nguyen T; Hamby A; Massa SM
    Proc Natl Acad Sci U S A; 2005 Aug; 102(33):11840-5. PubMed ID: 16087879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Depletion of p62 reduces nuclear inclusions and paradoxically ameliorates disease phenotypes in Huntington's model mice.
    Kurosawa M; Matsumoto G; Kino Y; Okuno M; Kurosawa-Yamada M; Washizu C; Taniguchi H; Nakaso K; Yanagawa T; Warabi E; Shimogori T; Sakurai T; Hattori N; Nukina N
    Hum Mol Genet; 2015 Feb; 24(4):1092-105. PubMed ID: 25305080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. scyllo-Inositol promotes robust mutant Huntingtin protein degradation.
    Lai AY; Lan CP; Hasan S; Brown ME; McLaurin J
    J Biol Chem; 2014 Feb; 289(6):3666-76. PubMed ID: 24352657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of a rat model of Huntington's disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors.
    Gabery S; Sajjad MU; Hult S; Soylu R; Kirik D; Petersén Å
    Eur J Neurosci; 2012 Sep; 36(6):2789-800. PubMed ID: 22731249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ciliogenesis is regulated by a huntingtin-HAP1-PCM1 pathway and is altered in Huntington disease.
    Keryer G; Pineda JR; Liot G; Kim J; Dietrich P; Benstaali C; Smith K; Cordelières FP; Spassky N; Ferrante RJ; Dragatsis I; Saudou F
    J Clin Invest; 2011 Nov; 121(11):4372-82. PubMed ID: 21985783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice.
    Apostol BL; Simmons DA; Zuccato C; Illes K; Pallos J; Casale M; Conforti P; Ramos C; Roarke M; Kathuria S; Cattaneo E; Marsh JL; Thompson LM
    Mol Cell Neurosci; 2008 Sep; 39(1):8-20. PubMed ID: 18602275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ubiquitin-interacting motifs inhibit aggregation of polyQ-expanded huntingtin.
    Miller SLH; Scappini EL; O'Bryan J
    J Biol Chem; 2007 Mar; 282(13):10096-10103. PubMed ID: 17276991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. N-terminal Huntingtin Knock-In Mice: Implications of Removing the N-terminal Region of Huntingtin for Therapy.
    Liu X; Wang CE; Hong Y; Zhao T; Wang G; Gaertig MA; Sun M; Li S; Li XJ
    PLoS Genet; 2016 May; 12(5):e1006083. PubMed ID: 27203582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.
    Wellington CL; Ellerby LM; Gutekunst CA; Rogers D; Warby S; Graham RK; Loubser O; van Raamsdonk J; Singaraja R; Yang YZ; Gafni J; Bredesen D; Hersch SM; Leavitt BR; Roy S; Nicholson DW; Hayden MR
    J Neurosci; 2002 Sep; 22(18):7862-72. PubMed ID: 12223539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inducing huntingtin inclusion formation in primary neuronal cell culture and in vivo by high-capacity adenoviral vectors expressing truncated and full-length huntingtin with polyglutamine expansion.
    Huang B; Schiefer J; Sass C; Kosinski CM; Kochanek S
    J Gene Med; 2008 Mar; 10(3):269-79. PubMed ID: 18067195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Selective degradation of expanded polyglutamine proteins by their specific recognition with QBP1].
    Nagai Y; Nukina N
    Rinsho Shinkeigaku; 2011 Nov; 51(11):1108-10. PubMed ID: 22277499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generation and Characterization of Knock-in Mouse Models Expressing Versions of Huntingtin with Either an N17 or a Combined PolyQ and Proline-Rich Region Deletion.
    André EA; Braatz EM; Liu JP; Zeitlin SO
    J Huntingtons Dis; 2017; 6(1):47-62. PubMed ID: 28211815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppression of polyglutamine-induced toxicity in cell and animal models of Huntington's disease by ubiquilin.
    Wang H; Lim PJ; Yin C; Rieckher M; Vogel BE; Monteiro MJ
    Hum Mol Genet; 2006 Mar; 15(6):1025-41. PubMed ID: 16461334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease.
    Chan EY; Luthi-Carter R; Strand A; Solano SM; Hanson SA; DeJohn MM; Kooperberg C; Chase KO; DiFiglia M; Young AB; Leavitt BR; Cha JH; Aronin N; Hayden MR; Olson JM
    Hum Mol Genet; 2002 Aug; 11(17):1939-51. PubMed ID: 12165556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Towards a transgenic model of Huntington's disease in a non-human primate.
    Yang SH; Cheng PH; Banta H; Piotrowska-Nitsche K; Yang JJ; Cheng EC; Snyder B; Larkin K; Liu J; Orkin J; Fang ZH; Smith Y; Bachevalier J; Zola SM; Li SH; Li XJ; Chan AW
    Nature; 2008 Jun; 453(7197):921-4. PubMed ID: 18488016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hsp40 gene therapy exerts therapeutic effects on polyglutamine disease mice via a non-cell autonomous mechanism.
    Popiel HA; Takeuchi T; Fujita H; Yamamoto K; Ito C; Yamane H; Muramatsu S; Toda T; Wada K; Nagai Y
    PLoS One; 2012; 7(11):e51069. PubMed ID: 23226463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
    Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
    Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Degradation of misfolded proteins by autophagy: is it a strategy for Huntington's disease treatment?
    Lin F; Qin ZH
    J Huntingtons Dis; 2013; 2(2):149-57. PubMed ID: 25063512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.